title: Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy.
authors.forename: Giselle C
authors.initials: GC
authors.lastname: Meléndez
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Jordan
authors.forename: Ralph B
authors.initials: RB
authors.lastname: D'Agostino
authors.forename: Sujethra
authors.initials: S
authors.lastname: Vasu
authors.forename: Craig A
authors.initials: CA
authors.lastname: Hamilton
authors.forename: W Gregory
authors.initials: WG
authors.lastname: Hundley
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D066126:Cardiotoxicity; D018450:Disease Progression; D005109:Extracellular Matrix / Q000473:pathology; D005260:Female; D005355:Fibrosis; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic